I'm sure this paper, published yesterday (June 2, 2018) in JAMA Oncology, will shed some lights to find a good answer to this question:

Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. Published online June 02, 2018. doi:10.1001/jamaoncol.2018.2706

Dear Andrés,

When we talk about disease burden, generally it is related to the impact of morbidity and mortality.

With that in mind, you could analyze the prevalence, hospitalizations and mortality rates.

The DALY can also help to estimate the impact, but it's most commun use for economic disease burden analysis.

Regards.

To the extent that you can impute cancer-free and progression-free years based on incidence and disease classification, you can also track the impact of improved prevention, diagnosis and treatment.

The recent big JAMAOncology paper used mortality, incidence,years of life lost YYL , years lived with disability YLD and DALYs (sum of YYL and YLD)

see paper on RG

GLOBAL BURDEN OF DISEASE CANCER COLLABORATION

(multiple authors incl J.LEIGH)

“Global,regional and national cancer incidence,

mortality,years of life lost, years lived with

disability and disability-adjusted life-years for

32 cancer groups,1990 to 2015- a systematic

analysis for the Global Burden of Disease Study

2015”

JAMA Oncology 3:524-548 (2017)

$��m�'_�

To start with, and if data allow, start with incidence rate (No. of new cases per 100000 population per year. This rate reflect the process of cancer "genesis" or contributory risk factors to the development of cancer. The next is mortality rate ( No. of deaths due to cancer per 100000 population per year). The third is case fatality rate/reciprocal of survival rate. The latter reflect the severity of cases and the effectiveness of health care. In my opinion these three parameters give basic idea about impact of cancer at population level. For further elaboration, other parameters as suggested by our colleagues are also useful.

Expected number of years lost is more precise and could also be included.

I think the answers given by James Leigh and other colleagues provide an overall pattern of any classical indicators that could be useful to weight the burden of disease from cancer in populations. I try to suggest just a complementary ("side") approach to the problem. Cancer in young people is especially heavy for a lot of manifest reasons, comprising (especially in low-income contexts) both the loss of contribution to familiar gains and work activities indispensable for the communities and the necessity to receive expensive therapies and care from elders. The calculation of the mean and median age of the cancer patients at the first diagnosis could provide some information about the burden of diasease upon individuals, families and local communities: certainly a very rough information, but simple and cheap to obtain even when financial difficulties could affect the possibility to conduct an epidemiological study.

Estimado Andrés, la carga de enfermedad para cualquier enfermedad es evaluada a través de los años de vida saludable perdidos (AVISA o DALY) que a su vez se obtienen de la suma de los años de vida perdidos por muerte prematura (AVP) así como de los años vividos con discapacidad (AVD). De este modo la carga de enfermedad tiene un componente no sólo de mortalidad sino también de discapacidad. Los demás indicadores como la incidencia y/o mortalidad son indicadores indirectos de la carga de enfermedad e insumos para el cálculo de los AVISA.

nice information

For practicality you can depend on incidence, years lived with disability and case fatality rate

I'm sure this paper, published yesterday (June 2, 2018) in JAMA Oncology, will shed some lights to find a good answer to this question:

Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. Published online June 02, 2018. doi:10.1001/jamaoncol.2018.2706